Skip to main content
SpringerLink
Log in

Antipsychotics

  • Chapter
  • First Online:
Psychiatric Drugs in Children and Adolescents

Abstract

Antipsychotics (previous name neuroleptics) are psychopharmacological agents employed primarily in the treatment of schizophrenia spectrum disorders, psychotic symptoms in other disorders (including affective and organic disorders), and mania. However, antipsychotics are also used in the treatment of children and adolescents with tic disorders and irritability, agitation, and aggression associated with autistic disorder and other pervasive developmental disorders, as well as in youths with disruptive behavior disorders with and without mental retardation (mostly off-label use).

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 79.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 99.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Literature

Selected Literature

  • AACAP Official Action (2001) Practice parameter for the assessment and treatment of children and adolescents with schizophrenia. J Am Acad Child Psychiatry 40(Suppl):S4–S23

    Google Scholar 

  • Aman MG, Mcdougle CJ, Scahill L, Handen B, Arnold E, Johnson C, Stigler KA, Bearss K, Butter E, Swiezy NB, Sukhodolsky DD, Ramadan Y, Pozdol SL, Nikolov R, Lecavalier L, Kohn AE, Koenig K, Hollway JA, Korzekwa P, Gavaletz A, Mulick JA, Hall KL, Dziura J, Ritz L, Trollinger S, Yu S, Vitiello B, Wagner A, for the Research Units on Pediatric Psychopharmacology Autism Network (2009) Medication and parent training in children with pervasive developmental disorders and serious behavior problems: results from a randomized clinical trial. J Am Acad Child Psychiatry 48:1143–1154

    Article  Google Scholar 

  • Amor LB (2012) Antipsychotics in pediatric and adolescent patients: a review of comparative safety data. J Affect Disord 138:S22–S30

    Article  PubMed  Google Scholar 

  • Ayanthi AR, Hickman IJ, Wang AYH, Jones AL, Newell F, Mowry BJ, Whitehead JP, Prins JB, MacDonald GA (2006) Olanzapine treatment is associated with reduced high molecular weight adiponectin in serum. J Clin Psychopharmacol 26:232–237

    Article  Google Scholar 

  • Baptista T, Kin Y, Beaulieu S, de Baptista EA (2002) Obesity and related metabolic abnormalities during antipsychotic drug administration: mechanisms, management and research perspectives. Pharmacopsychiatry 35:205–219

    Article  CAS  PubMed  Google Scholar 

  • Benes FM (2009) Neural circuitry models of schizophrenia: is it dopamine, GABA, glutamate, or something else? Biol Psychiatry 65:1003–1005

    Article  PubMed  Google Scholar 

  • Brown AS (2011) The environment and susceptibility to schizophrenia. Prog Neurobiol 93:23–58

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Campbell M, Small AM, Green WH, Jennings MA, Perry R, Bennett WG, Anderson L (1984) A comparison of haloperidol and lithium in hospitalized aggressive conduct disordered children. Arch Gen Psychiatry 41:650–656

    Article  CAS  PubMed  Google Scholar 

  • Carlsson A (2006) The neurochemical circuitry of schizophrenia. Pharmacopsychiatry 39(Suppl 1):S10–S14

    Article  CAS  PubMed  Google Scholar 

  • Carlsson A, Lindqvist M (1963) Effect of chlorpromazine or haloperidol on formation of 3-methoxytyramine and normetanephrine in mouse brain. Acta Pharmacol Toxicol 20:140–144

    Article  CAS  Google Scholar 

  • Carpenter WT, Davis JM (2012) Perspective. Another view of the history of antipsychotic drug discovery and development. Mol Psychiatry 17:1168–1173

    Article  CAS  PubMed  Google Scholar 

  • Cohen D, Huinink S (2007) Atypical antipsychotic-induced diabetes mellitus in child and adolescent psychiatry. CNS Drugs 21:1035–1038

    Article  PubMed  Google Scholar 

  • Comai S, Tau M, Pavlovic Z, Gobbi G (2012) The psychopharmacology of aggressive behavior: a translational approach. Part 2: clinical studies using atypical antipsychotics, anticonvulsants, and lithium. J Clin Psychopharmacol 32:237–260

    Article  CAS  PubMed  Google Scholar 

  • Correll CU (2008) Antipsychotic use in children and adolescents: minimizing adverse effects to maximize outcomes. J Am Acad Child Psychiatry 47:9–20

    Article  Google Scholar 

  • Correll CU (2011) Antipsychotic agents: traditional and atypical. In: Martin A, Scahill L, Kratochvil CJ (eds) Pediatric psychopharmacology: principles and practice, 2nd edn. Oxford University Press, New York, pp 312–337

    Google Scholar 

  • Correll CH, Carlson HE (2006) Endocrine and metabolic adverse effects of psychotropic medications in children and adolescents. J Am Acad Child Psychiatry 45:771–791

    Google Scholar 

  • Correll CU, Kane JM (2007) One-year incidence rates of tardive dyskinesia in children and adolescents treated with second-generation antipsychotics: a systematic review. J Child Adolesc Psychopharmacol 17:647–655

    Article  PubMed  Google Scholar 

  • Correll CU, Sheridan EM, DelBello MP (2010) Antipsychotic and mood stabilizer efficacy and tolerability in pediatric and adult patients with bipolar I mania: a comparative analysis of acute, randomized, placebo-controlled trials. Bipolar Disord 12:116–141

    Article  CAS  PubMed  Google Scholar 

  • Correll CU, Kratochvil CJ, March JS (2011) Development in pediatric psychopharmacology: focus on stimulants, antidepressants, and antipsychotics. J Clin Psychiatry 72:655–670

    Article  PubMed  Google Scholar 

  • Creese I, Burt DR, Snyder SH (1976) Dopamine receptors binding predicts clinical potencies of antischizophrenic drugs. Science 192:481–483

    Article  CAS  PubMed  Google Scholar 

  • DeNayer A, DeHert M, Scheen A, Van Gaal L, Peuskens J (2007) Belgian consensus on metabolic problems associated with atypical antipsychotics. Encéphale 33:197–202

    Article  CAS  Google Scholar 

  • Egberts K, Mehler-Wex C, Gerlach M (2011) Therapeutic drug monitoring in child and adolescent psychiatry. Pharmacopsychiatry 44:249–253

    Article  CAS  PubMed  Google Scholar 

  • Eggers C, Rothenberger A, Berghaus U (1988) Clinical and neurobiological findings in children suffering from tic disease following treatment with tiapride. Eur Arch Psychiatry Neurol Sci 237:223–229

    Article  CAS  PubMed  Google Scholar 

  • Fleischhaker C, Heiser P, Hennighausen K, Herpertz-Dahlmann B, Holtkamp K, Mehler-Wex C, Rauh H, Remschmidt H, Schulz E, Warnke A (2008) Weight gain in children and adolescents during 45 weeks treatment with clozapine, olanzapine and risperidone. J Neural Transm 115:1599–1608

    Article  CAS  PubMed  Google Scholar 

  • Fraguas D, Correll CU, Merchán-Naranjo J, Rapado-Castro M, Parellada M, Moreno C, Arango C (2011) Efficacy and safety of second-generation antipsychotics in children and adolescents with psychotic and bipolar spectrum disorders: comprehensive review of prospective head-to-head and placebo-controlled comparisons. Eur Neuropsychopharmacol 21:621–645

    Article  CAS  PubMed  Google Scholar 

  • Gebicke-Haerter PJ (2012) Epigenetics of schizophrenia. Pharmacopsychiatry 45(Suppl 1):S42–S48

    CAS  PubMed  Google Scholar 

  • Gerlach M, Hünnerkopf R, Rothenhöfer S, Libal G, Burger R, Clement HW, Fegert JM, Wewetzer CH, Mehler-Wex C (2007) Therapeutic drug monitoring of quetiapine in adolescents with psychotic disorders. Pharmacopsychiatry 40:72–76

    Article  CAS  PubMed  Google Scholar 

  • Glassman AH, Bigger T (2001) Antipsychotic drugs: prolonged QTc interval, Torsade de pointes and sudden death. Am J Psychiatry 158:1774–1782

    Article  CAS  PubMed  Google Scholar 

  • Goedhard LE, Stolker JJ, Herrdink ER, Nijman HL, Olivier B, Egberts CG (2006) Pharmacotherapy of aggressive behavior in general adult psychiatry: a systematic review. J Clin Psychiatry 67:1013–1024

    Article  CAS  PubMed  Google Scholar 

  • Goldstein BI, Sassi R, Diler RS (2012) Pharmacological treatment of bipolar disorder in children and adolescents. Child Adolesc Psychiatr Clin N Am 21:911–939

    Article  PubMed  Google Scholar 

  • Gracious BL, Krysiak TE, Youngstrom EA (2002) Amantadine treatment of psychotropic-induced weight gain in children and adolescents: case series. J Child Adolesc Psychopharmacol 12:249–257

    Article  PubMed  Google Scholar 

  • Grohmann R, Hippius H, Rüther R (2001) Extrapyramidal motor side-effects and blood profile changes. Stumbling blocks in psychiatric pharmacotherapy. MMW-Fortschr Med 77(Suppl 2):76–77

    Google Scholar 

  • Haase HJ (1954) About prevalence and interpretation of the psychomotor Parkinson syndrome in megaphen or largactil treatment duration. Nervenarzt 25:486–492

    CAS  PubMed  Google Scholar 

  • Haase HJ, Janssen PAJ (1965) The action of neuroleptic drugs. Year Book Medical, Chicago

    Google Scholar 

  • Henderson DC, Cagliero E, Copeland PM, Louie PM, Borba CP, Fan X, Freudenreich O, Gogg DC (2007) Elevated hemoglobin A1c as possible indicator of diabetes mellitus and diabetic ketoacidosis in schizophrenia patients receiving atypical antipsychotics. J Clin Psychiatry 68:533–541

    Article  CAS  PubMed  Google Scholar 

  • Hiemke C, Baumann P, Bergemann N, Conca A, Dietmaier O, Egberts K, Fric M, Gerlach M, Greiner C, Gründer G, Haen E, Havemann-Reinecke U, Jaquenoud Sirot E, Kirchherr H, Laux G, Lutz UC, Messer T, Müller MJ, Pfuhlmann B, Rambeck B, Riederer P, Schoppek B, Stingl J, Uhr M, Ulrich S, Waschgler R, Zernig G, The TDM group of the AGNP (2011) AGNP consensus guidelines for therapeutic drug monitoring in psychiatry – update 2011. Pharmacopsychiatry 44:195–235

    Article  Google Scholar 

  • Kapur S, Seeman P (2000) Antipsychotic agents differ in how fast they come off the dopamine D2 receptors. Implications for atypical antipsychotic action. J Psychiatry Neurosci 25:161–166

    CAS  PubMed Central  PubMed  Google Scholar 

  • Kapur S, Seeman P (2001) Does fast dissociation from the dopamine D2 receptor explain the action of atypical antipsychotics? A new hypothesis. Am J Psychiatry 158:360–369

    Article  CAS  PubMed  Google Scholar 

  • Keefe RSE, Bilder RM, Davis SM, Harvey PD, Palmer BW, Gold JM, Meltzer HY, Green MF, Capuano G, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Davis CE, Hsiao JK, Lieberman JA, CATIE investigators and the Neurocognitive Working Group (2007) Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial. Arch Gen Psychiatry 64:633–647

    Article  CAS  PubMed  Google Scholar 

  • Khandaker GM, Zimbron J, Dalman C, Lewis G, Jones PB (2012) Childhood infection and adult schizophrenia: a meta-analysis of population-based studies. Schizophr Res 139:161–168

    Article  PubMed Central  PubMed  Google Scholar 

  • Klampfl K, Taurines R, Preuss A, Burger R, Rothenhöfer S, Wewetzer C, Pfuhlmann B, Fegert J, Gerlach M, Mehler-Wex C (2010) Serum concentrations, therapeutic response and side effects in children and adolescents with impulsive-aggressive symptoms during risperidone therapy. Pharmacopsychiatry 43:58–65

    Article  CAS  PubMed  Google Scholar 

  • Koller E, Schneider B, Bennett K, Dubitsky G (2001) Clozapine-associated diabetes. Am J Med 111:716–723

    Article  CAS  PubMed  Google Scholar 

  • Koller EA, Cross JT, Schneider B (2004a) Risperidone-associated diabetes mellitus in children. Pediatrics 113:421–422

    Article  PubMed  Google Scholar 

  • Koller EA, Weber J, Doraiswamy PM, Schneider BS (2004b) A survey of reports of quetiapine-associated hyperglycemia and diabetes mellitus. J Clin Psychiatry 65:857–863

    Article  CAS  PubMed  Google Scholar 

  • Kulkarni SK, Naidu PS (2003) Pathophysiology and drug therapy of tardive dyskinesia: current concepts and future perspectives. Drug Today 39:19–49

    Article  CAS  Google Scholar 

  • Kumra S, Herion D, Jacobsen LK, Briguglia C, Grothe D (1997) Case study: risperidone-induced hepatotoxicity in pediatric patients. J Am Acad Child Psychiatry 36:701–705

    Article  CAS  Google Scholar 

  • Lessig MC, Shapira NA, Murphy TK (2001) Topiramate reversing atypical antipsychotic weight gain. Letter. J Am Acad Child Psychiatry 40:1364

    Article  CAS  Google Scholar 

  • Leucht S, Corves C, Arbter D, Engel RR, Li C, Davis JM (2009) Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 373:31–41

    Article  CAS  PubMed  Google Scholar 

  • Lieberman JA (2004) Dopamine partial agonists. A new class of antipsychotics. CNS Drugs 18:251–267

    Article  CAS  PubMed  Google Scholar 

  • Liu HY, Potter MP, Woodworth KY, Yorks DM, Petty CR, Wozniak JR, Faraone SV, Biederman J (2011) Pharmacologic treatments for pediatric bipolar dis-order: a review and meta-analysis. J Am Acad Child Psychiatry 50:749–762

    Google Scholar 

  • Lopez-Munoz F, Alamo C, Cuenca E, Shen WW, Clervoy P, Rubio G (2005) History of the discovery and clinical introduction of chlorpromazine. Ann Clin Psy-chiatry 17:113–135

    Google Scholar 

  • Madaan V, Dvir Y, Wilson DR (2008) Child and adolescent schizophrenia: pharmacological approaches. Exp Opin Pharmacol 9:2053–2068

    Article  CAS  Google Scholar 

  • Marenco S, Weinberger DR (2000) The neurodevelopmental hypothesis of schizophrenia: following a trail of evidence from cradle to grave. Dev Psychopathol 12:501–527

    Article  CAS  PubMed  Google Scholar 

  • Masi G, Liboni F (2011) Management of schizophrenia in children and adolescents. Drugs 71:179–208

    Article  PubMed  Google Scholar 

  • Mishara AL, Goldberg TE (2004) A meta-analysis and critical review of the effects of conventional neuroleptic treatment on cognition in schizophrenia: opening a closed book. Biol Psychiatry 55:1013–1022

    Article  CAS  PubMed  Google Scholar 

  • Miyamoto S, Duncan GE, Marx CE, Lieberman JA (2005) Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs. Mol Psychiatry 10:79–104

    Article  CAS  PubMed  Google Scholar 

  • Morrison JA, Cottingham EM, Barton BA (2002) Metformin for weight loss in pediatric patients taking psychotropic drugs. Am J Psychiatry 159:655–657

    Article  PubMed  Google Scholar 

  • Mutschler E, Geisslinger G, Kroemer HK, Ruth P, Schäfer-Korting M (2008) Mutschler Arzneimittelwirkungen. Lehrbuch der Pharmakologie und Toxikologie, 9th edn. Wissenschaftliche Verlagsgesellschaft, Stuttgart

    Google Scholar 

  • Nevels RM, Dehon EE, Alexander K, Gontkovsky ST (2010) Psychopharmacology of aggression in children and adolescents with primary neuropsychiatric disorders: a review of current and potentially promising treatment options. Exp Clin Psychopharmacol 18:184–201

    Article  PubMed  Google Scholar 

  • Patteet L, Morrens M, Maudens KE, Niemegeers P, Sabbe B, Neels H (2012) Therapeutic drug monitoring of common antipsychotics. Ther Drug Monit 34:629–651

    Article  CAS  PubMed  Google Scholar 

  • Pool D, Bloom W, Mielke DH, Roniger JJ, Gallant DM (1976) Controlled evaluation of loxitane in 75 adolescent schizophrenic patients. Curr Ther Res Clin Exp 19:99–104

    CAS  PubMed  Google Scholar 

  • Pringsheim T, Lam D, Ching H, Patten S (2011) Metabolic and neurological complications of second-generation antipsychotic use in children. Drug Saf 34:651–668

    Google Scholar 

  • Pringsheim T, Gorman D (2012) Second-generation antipsychotics for the treatment of disruptive behaviour disorders in children: a systematic review. Can J Psychiatry 57:722–727

    PubMed  Google Scholar 

  • Realmuto GM, Erickson WD, Yellin AM, Hopwood JH, Greenberg LM (1984) Clinical comparison of thiothixene and thioridazine in schizophrenic adolescents. Am J Psychiatry 141:440–442

    CAS  PubMed  Google Scholar 

  • Reyes M, Buitelaar J, Toren P, Augustyns I, Eerdekens M (2006) A randomized, double-blind, placebo-controlled study of risperidone maintenance treatment in children and adolescents with disruptive behavior disorders. Am J Psychiatry 163:402–410

    Article  PubMed  Google Scholar 

  • Robb AS, Carson WH, Nyilas M, Ali M, Forbes RA, Iwamoto T, Assunção-Talbott S, Whitehead R, Pikalov A (2010) Changes in positive and negative syndrome scale-derived hostility factor in adolescents with schizophrenia treated with aripiprazole: post-hoc analysis of randomized clinical trial data. J Child Adolesc Psychopharmacol 20:33–38

    Article  PubMed  Google Scholar 

  • Sallee FR, Kurlan R, Goetz CG, Singer H, Scahill L, Law G, Dittman VM, Chappell PB (2000) Ziprasidone treatment of children and adolescents with Tourette’s syndrome: a pilot study. J Am Acad Child Psychiatry 39:292–299

    Article  CAS  Google Scholar 

  • Scahill L, Lechman JF, Schultz RT, Katsovich L, Peterson BS (2003) A placebo-controlled trial of risperidone in Tourette syndrome. Neurology 60:1130–1135

    Article  CAS  PubMed  Google Scholar 

  • Schatzberg AF, Cole JO, De Battista C (2003) Manual of clinical psychopharmacology, 4th edn. American Psychiatric Publishing, Washington, DC

    Google Scholar 

  • Schimmelmann BG, Schmidt SJ, Carbon M, Correll CU (2013) Treatment of adolescents with early-onset schizophrenia spectrum disorders: in search of a rational, evidence-informed approach. Curr Opin Psy-chiatry 26:219–230

    Google Scholar 

  • Seeman P (2002) Atypical antipsychotics: mechanism of action. Can J Psychiatry 47:27–38

    PubMed  Google Scholar 

  • Seeman P, Lee T (1975) Antipsychotic drugs: direct correlation between clinical potency and presynaptic action on dopamine neurons. Science 188:1217–1219

    Article  CAS  PubMed  Google Scholar 

  • Seida JC, Schouten JR, Boylan K, Newton AS, Mousavi SS, Beaith A, Vandermeer B, Dryden DM, Carrey N (2012) Antipsychotics for children and youth adults: a comparative effectiveness review. Pediatrics 129:e771–e784

    Article  PubMed  Google Scholar 

  • Silva RR, Munoz DM, Alpert M, Perlmutter IR, Diaz J (1999) Neuroleptic malignant syndrome in children and adolescents. J Am Acad Child Psychiatry 38:187–194

    Article  CAS  Google Scholar 

  • Spencer EK, Kafantaris V, Padron-Gayol MV, Rosenberg CR (1992) Haloperidol in schizophrenic children: early findings from a study in progress. Psy-chopharmacol Bull 28:183–186

    Google Scholar 

  • Stigler KA, Potenza MN, Posey DJ, McDougle CJ (2004) Weight gain associated with atypical antipsychotic use in children and adolescents. Prevalence, clinical relevance, and management. Paediatr Drugs 6:33–44

    Article  PubMed  Google Scholar 

  • Szigethy E, Wiznitzer M, Branicky LA, Maxwell K, Findling RL (1999) Risperidone-induced hepatotoxicity in children and adolescents? A chart review. J Child Adolesc Psychopharmacol 9:93–98

    Article  CAS  PubMed  Google Scholar 

  • Tamminga CA (2006) Principles of pharmacology of schizophrenia. In: Charney DS, Nestler EJ (eds) Neurobiology of mental illnesses, 2nd edn. Oxford University Press, Oxford/New York, pp 339–354

    Google Scholar 

  • Zuddas A, Zanni R, Usala T (2011) Second generation antipsychotics (SGAs) for non-psychotic disorders in children and adolescents: a review of the randomized controlled studies. Eur Neuropsychopharmacol 21:600–620

    Article  CAS  PubMed  Google Scholar 

Further Reading

  • Remschmidt H (ed) (2001) Schizophrenia in children and adolescents. Cambridge University Press, Cambridge

    Google Scholar 

  • Schatzberg AF, Nemeroff CB (eds) (2009) Textbook of psychopharmacology, 4th edn. American Psychiatric Publishing, Washington, DC/London

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy, Laboratory for Clinical Neurobiology and Therapeutic Drug Monitoring, University of Würzburg, Füchsleinstr. 15, 97080, Würzburg, Germany

    Manfred Gerlach PhD

  2. Department of Child and Adolescent Psychiatry and Psychotherapy, University of Ulm, Steinhövelstr. 5, 89075, Ulm, Germany

    Claudia Mehler-Wex MD

  3. HEMERA-Klinik, Schönbornstr. 16, 97688, Bad Kissingen, Germany

    Claudia Mehler-Wex MD

  4. University Hospital of Child and Adolescent Psychiatry, University of Bern, Bolligenstr. 111, 3000, Bern, Switzerland

    Benno G. Schimmelmann MD

Authors
  1. Manfred Gerlach PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Claudia Mehler-Wex MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Benno G. Schimmelmann MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Manfred Gerlach PhD .

Editor information

Editors and Affiliations

  1. Kinder- und Jugendpsychiatrie, Universitätsklinikum Würzburg Klinik und Poliklinik, Würzburg, Germany

    Manfred Gerlach

  2. Jugendpsychiatrie und Psychotherapie, Universitätsklinikum Würzburg Klinik und Poliklinik für Kinder- und, Würzburg, Germany

    Andreas Warnke

  3. Child and Adolescent Psychiatry New York Presbyterian Hospital, New York, New York, USA

    Laurence Greenhill

Rights and permissions

Reprints and permissions

Copyright information

© 2014 Springer-Verlag Wien

About this chapter

Cite this chapter

Gerlach, M., Mehler-Wex, C., Schimmelmann, B.G. (2014). Antipsychotics. In: Gerlach, M., Warnke, A., Greenhill, L. (eds) Psychiatric Drugs in Children and Adolescents. Springer, Vienna. https://doi.org/10.1007/978-3-7091-1501-5_5

Download citation

  • DOI: https://doi.org/10.1007/978-3-7091-1501-5_5

  • Published:

  • Publisher Name: Springer, Vienna

  • Print ISBN: 978-3-7091-1500-8

  • Online ISBN: 978-3-7091-1501-5

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation